Skip to content
Companies

Biolexis Therapeutics

Oral GLP-1 pills for obesity and type 2 diabetes

Raised to date

$1.6M

of $12M offered across 1 Form D filing

Still open
$10.4M
Investors
2
Last filed
Jun 3, 2026

About

Biolexis Therapeutics is a clinical-stage biopharmaceutical company in Lehi, Utah, developing oral small-molecule therapies for metabolic disease. Its lead programs are a first-in-class allosteric GLP-1 receptor agonist and a first-in-class AMPK activator, designed to deliver injectable-level efficacy in a daily pill with better tolerability. The company uses an AI-driven discovery platform, MolecuLern, that optimizes for oral bioavailability, tolerability, and low drug-drug interaction risk from the earliest stages of design. It was founded in 2021 by David J. Bearss and Hariprasad Vankayalapati.

Designs oral GLP-1 and AMPK drugs for tolerability from the start: BLX-7006 reported 0% GI-related discontinuation in Phase 1 and BLX-0871 showed no cardiac biomarker abnormalities, addressing the two failure modes that have limited injectable GLP-1s and prior AMPK programs.

Funding

  • OtherFiled Jun 3, 2026Form D
    $1.6M/ $12M

Product

BLX-7006

Clinical-stage small-molecule therapeutic

A first-in-class allosteric oral GLP-1 receptor agonist for obesity and type 2 diabetes, which has completed a first-in-human Phase 1 trial.

  • Allosteric activation of the GLP-1 receptor
  • Oral, once-daily dosing
  • 0% GI-related discontinuation reported in Phase 1

Built for

Patients with obesity and type 2 diabetes, reached through pharmaceutical partners, prescribers, and payers

People on file